Fulgent Genetics (FLGT) Cash from Investing Activities (2015 - 2026)

Fulgent Genetics has disclosed Cash from Investing Activities across 12 years of filings, most recently posting $10.9 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $10.9 million, down 60.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $94.6 million (up 471.04% YoY), and the FY2025 annual result was $111.4 million, up 290.86% from the prior year.
• Cash from Investing Activities came in at $10.9 million for Q1 2026 at Fulgent Genetics, down from $11.2 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $53.4 million in Q2 2025 to a low of -$213.7 million in Q2 2022.
• The 5-year median for Cash from Investing Activities is $9.0 million (2024), against an average of -$9.3 million.
• Peak annual rise in Cash from Investing Activities reached 766.42% in 2024, while the deepest fall reached 983.74% in 2024.
• Fulgent Genetics' Cash from Investing Activities stood at -$92.6 million in 2022, then soared by 126.21% to $24.3 million in 2023, then sank by 213.12% to -$27.5 million in 2024, then surged by 140.63% to $11.2 million in 2025, then retreated by 1.93% to $10.9 million in 2026.
• The last three Cash from Investing Activities figures came in at $10.9 million (Q1 2026), $11.2 million (Q4 2025), and $19.1 million (Q3 2025), per Business Quant data.